GlassScriptPhysician profile
Andrea Partida
NPI 1992151948
$5,225.67
in general payments reported to CMS, 2019-2025
14 companies · $681 in 2025
The $681 reported for 2025 was more than what 86% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $106 · 2020: $114 · 2021: $3,834 · 2022: $171 · 2023: $146 · 2024: $175 · 2025: $681.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,001.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,001.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $3,844.40 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $223.90 | 2022-2025 | |
| Hologic Sales and Service, LLC | $172.72 | 2024-2025 | Thinprep 2000 Processor, Aptima, Myosure Tissue Removal Device |
| Shield Therapeutics INC | $162.12 | 2025 | |
| Organon LLC | $159.05 | 2022-2025 | Nexplanon |
| Coopersurgical, INC. | $153.88 | 2020-2025 | Endosee, Paragard T 380a |
| Abbvie INC. | $152.24 | 2019-2025 | |
| Exeltis, USA INC. | $130.32 | 2022-2025 | Slynd |
| Mayne Pharma Commercial LLC | $109.39 | 2024-2025 | |
| Astellas Pharma US INC | $41.09 | 2023-2025 | Veozah |
| Pfizer INC. | $24.98 | 2022 | |
| Sumitomo Pharma America, INC. | $19.77 | 2025 | Myfembree |
| Millicent US INC | $18.22 | 2024 | Femring, Intrarosa |
| Therapeuticsmd, INC. | $13.59 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrea Partida listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.